BioRestorative Therapies : BRTX Presentation May 2022

1

FORWARD LOOKING STATEMENT

STATEMENTS IN THIS PRESENTATION, INCLUDING THE INFORMATION SET FORTH AS TO THE FUTURE FINANCIAL OR OPERATING PERFORMANCE OF BIORESTORATIVE THERAPIES, INC. (THE "COMPANY") THAT ARE NOT CURRENT OR HISTORICAL FACTUAL STATEMENTS MAY CONSTITUTE "FORWARD LOOKING" INFORMATION WITHIN THE MEANING OF THE U.S. FEDERAL AND STATE SECURITIES LAWS. WHEN USED IN THIS PRESENTATION, SUCH STATEMENTS MAY INCLUDE, AMONG OTHER TERMS, SUCH WORDS AS "MAY," "WILL," "EXPECT," "BELIEVE," "PLAN," "ANTICIPATE," "INTEND," "ESTIMATE," "PROJECT," "TARGET" AND OTHER SIMILAR TERMINOLOGY. THESE STATEMENTS REFLECT CURRENT EXPECTATIONS, ESTIMATES AND PROJECTIONS REGARDING FUTURE EVENTS AND OPERATING PERFORMANCE AND SPEAK ONLY AS TO THE DATE OF THIS PRESENTATION. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD LOOKING STATEMENTS AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE.

FORWARD LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER IMPORTANT FACTORS THAT COULD CAUSE OUR ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS, BUSINESS PLAN OR INDUSTRY RESULTS, TO DIFFER MATERIALLY FROM OUR EXPECTATIONS OF FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY THESE FORWARD LOOKING STATEMENTS. THESE FORWARD LOOKING STATEMENTS MAY NOT BE REALIZED DUE TO A VARIETY OF FACTORS, INCLUDING WITHOUT LIMITATION: (I) OUR LIMITED OPERATING HISTORY, LACK OF SIGNIFICANT REVENUES, AND SUBSTANTIAL LOSSES SINCE INCEPTION;(II) OUR ABILITY TO OBTAIN SUFFICIENT FINANCING TO INITIATE AND COMPLETE OUR CLINICAL TRIALS AND FUND OUR OPERATIONS; (III) OUR ABILITY TO TIMELY AND SUCCESSFULLY DEVELOP AND COMMERCIALIZE BRTX-100, OUR LEAD PRODUCT CANDIDATE FOR THE TREATMENT OF CHRONIC LUMBAR DISC DISEASE; (IV) DELAYS IN ENROLLING PATIENTS IN OUR CLINICAL TRIALS; (V) DISRUPTION TO OUR ACCESS TO THE MEDIA (INCLUDING CELL CULTURE MEDIA) AND REAGENTS THE COMPANY IS USING IN THE CLINICAL DEVELOPMENT OF OUR CELL THERAPY PRODUCT CANDIDATES; (VI) FAILURE OF OUR CLINICAL TRIALS TO DEMONSTRATE ADEQUATELY THE SAFETY AND EFFICACY OF OUR PRODUCT CANDIDATES; (VII) OUR LACK OF MANUFACTURING CAPABILITIES TO PRODUCE OUR PRODUCT CANDIDATES AT COMMERCIAL SCALE QUANTITIES AND LACK OF AN ALTERNATIVE MANUFACTURING SUPPLY; (VIII) A LOSS OF OUR EXCLUSIVE LICENSE RIGHTS WITH REGARD TO OUR DISC/SPINE TECHNOLOGY; (IX) SAFETY PROBLEMS ENCOUNTERED BY US OR OTHERS DEVELOPING NEW STEM CELL- BASED THERAPIES; (X) ETHICAL AND OTHER CONCERNS SURROUNDING THE USE OF STEM CELL THERAPY WHICH NEGATIVELY IMPACT THE PUBLIC PERCEPTION OF OUR STEM CELL PRODUCTS AND/OR SERVICES; (XI) OUR LIMITED EXPERIENCE IN THE DEVELOPMENT AND MARKETING OF CELL THERAPIES; (XII) OUR RELIANCE ON NOVEL TECHNOLOGIES THAT ARE INHERENTLY EXPENSIVE AND RISKY; (XIII) SIGNIFICANT PRODUCT LIABILITY CLAIMS AND LITIGATION TO WHICH THE COMPANY MAY BE SUBJECT, INCLUDING POTENTIAL EXPOSURE FROM THE USE OF OUR PRODUCT CANDIDATES IN HUMAN SUBJECTS; (XIV) OUR INABILITY TO OBTAIN REIMBURSEMENT FOR OUR PRODUCTS AND SERVICES FROM PRIVATE AND GOVERNMENTAL INSURERS; (XV) OUR INABILITY TO PROTECT OUR PROPRIETARY RIGHTS; AND (XVI) COMPLIANCE WITH APPLICABLE FEDERAL, STATE, LOCAL, AND INTERNATIONAL

REQUIREMENTS. SEE ALSO "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS - FACTORS THAT MAY AFFECT FUTURE RESULTS AND FINANCIAL CONDITION" SET FORTH IN THE

COMPANY'S MOST RECENT ANNUAL REPORT FILED WITH THE SEC.

MANY OF THESE ISSUES CAN AFFECT THE COMPANY'S ACTUAL RESULTS AND COULD CAUSE THE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED IN ANY FORWARD LOOKING STATEMENTS MADE BY, OR ON BEHALF OF, THE COMPANY. YOU ARE CAUTIONED THAT FORWARD LOOKING STATEMENTS ARE NOT GUARANTEES OF FUTURE PERFORMANCE, AND YOU SHOULD NOT PLACE RELIANCE ON THEM. IN FORMULATING THE FORWARD LOOKING STATEMENTS CONTAINED IN THIS PRESENTATION, IT HAS BEEN ASSUMED THAT BUSINESS AND ECONOMIC CONDITIONS AFFECTING THE COMPANY AND THE ECONOMY GENERALLY WILL CONTINUE SUBSTANTIALLY IN THE ORDINARY COURSE. THESE ASSUMPTIONS, ALTHOUGH CONSIDERED REASONABLE AT THE TIME OF PREPARATION, MAY PROVE TO BE INCORRECT.

THE DESCRIPTION OF THE COMPANY AND ITS BUSINESS IN THIS PRESENTATION DOES NOT PURPORT TO BE COMPLETE AND IS SUBJECT TO THE MORE DETAILED DESCRIPTION OF THE

COMPANY AND ITS BUSINESS IN THE COMPANY'S ANNUAL, QUARTERLY AND CURRENT REPORTS FILED WITH THE SEC.

2

LEADERSHIP

LANCE ALSTODT

Chairman & CEO

Lance leads BRTX's mission to improve the

lives of patients through the use of Regenerative Medicine

Lance spent over 30 years leading, advising and operating companies within the Healthcare sector. He is the founder of MedVest Capital, a Healthcare fund created in 2013 and prior to that led the Medical Technology Investment banking group at Bank of America Merrill Lynch and Leerink Partners.

ROBERT KRISTAL

Chief Financial Officer

Robert has a versatile background of over 25 years on Bay Street and Wall Street

Robert most recently was the DOR for a Healthcare focused Investment Bank. His career has spanned Trading, Sales, Investment Banking and Research.

FRANCISCO SILVA

Vice President of R&D

Francisco has over 20 years of experience in the development of cell based and off the shelf therapeutics.

Francisco has obtained a number of issued patents in cell therapy, and has manuscripts published with regard to translational stem cell research.

3

COMPANY HIGHLIGHTS

Disruptive Platform Technologies in Cellular Therapy

Strong Preliminary Data Indicative of Positive Trial Outcomes

Active Phase 2 Trial in Spine

Addressing Multi-Billion Dollar Markets with Unmet Needs

Opportunity for Key Strategic Partnerships

Multiple Near-Term Value Enhancing Inflection Points

Strong Intellectual Property Protection

Experienced Management Team & Scientific Advisory Board

4

Autologous

Allogeneic

A Platform Technology

Preclinical

Phase 1

Phase 2

Phase 3

Spine

Lumbar

Cervical

Thoracic

Osteoarthritis

Hips/Knees

Extremities

Avascular Zones

Brown Fat Cells

Type 2 Diabetes

Obesity

PCOS

Covid-19

Brown Adipose Stem Cells

ARDS

Long Hauler Covid

Gene Modification

BRTX 200 Polymer/Crispr

5